Piper Sandler raised the firm’s price target on Alignment Healthcare to $10 from $8 and keeps an Overweight rating on the shares. The firm notes Alignment reported a $46M Q2 revenue beat vs. the high end of guidance. Adjusted gross profit and adjusted EBITDA came in at the high ends of respective ranges.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALHC:
- Alignment Healthcare price target raised to $7 from $4.50 at Barclays
- Alignment Healthcare sees FY24 revenue $2.61B-$2.64B, consensus $2.52B
- Alignment Healthcare sees Q3 revenue $655M-$665M, consensus $630.25M
- Alignment Healthcare reports Q2 EPS (13c), consensus (14c)
- Better Health Outcomes for Seniors, Improved Access to Care and Reduced Environmental Footprint Are Top Achievements Noted in Alignment Healthcare’s 3rd Annual ESG Report